AVXL vs. MGTX, OCGN, GLUE, SOPH, JSPR, IVVD, MGX, SLDB, BDTX, and TCRX
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include MeiraGTx (MGTX), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), SOPHiA GENETICS (SOPH), Jasper Therapeutics (JSPR), Invivyd (IVVD), Metagenomi (MGX), Solid Biosciences (SLDB), Black Diamond Therapeutics (BDTX), and TScan Therapeutics (TCRX). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences (NASDAQ:AVXL) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by insiders. Comparatively, 9.7% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Anavex Life Sciences currently has a consensus price target of $40.00, suggesting a potential upside of 1,062.79%. MeiraGTx has a consensus price target of $25.67, suggesting a potential upside of 434.72%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than MeiraGTx.
In the previous week, Anavex Life Sciences had 6 more articles in the media than MeiraGTx. MarketBeat recorded 8 mentions for Anavex Life Sciences and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.48 beat Anavex Life Sciences' score of 0.01 indicating that MeiraGTx is being referred to more favorably in the news media.
Anavex Life Sciences has higher earnings, but lower revenue than MeiraGTx. Anavex Life Sciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Anavex Life Sciences has a net margin of 0.00% compared to MeiraGTx's net margin of -599.47%. Anavex Life Sciences' return on equity of -30.32% beat MeiraGTx's return on equity.
Anavex Life Sciences received 236 more outperform votes than MeiraGTx when rated by MarketBeat users. Likewise, 74.08% of users gave Anavex Life Sciences an outperform vote while only 71.10% of users gave MeiraGTx an outperform vote.
Summary
Anavex Life Sciences beats MeiraGTx on 10 of the 16 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
